A Study of LXI-15029 in Patients With Advanced Malignant Solid Tumors
Status:
Recruiting
Trial end date:
2021-10-28
Target enrollment:
Participant gender:
Summary
1. To evaluate the safety and tolerability of LXI-15029 in Chinese patients with advanced
malignant solid tumors in monotherapy period, including confirmation of the maximum tolerated
dose (MTD) of monotherapy. 2.To evaluate the safety and tolerability of LXI-15029 in Chinese
postmenopausal patients with metastatic or locally advanced breast cancer with estrogen
receptor (+) and human epidermal growth factor receptor 2 (-) in combined with Exemestane
period , including confirmation of the maximum tolerated dose(MTD) of the combined therapy
with Exemestane.
Phase:
Phase 1
Details
Lead Sponsor:
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.